123 related articles for article (PubMed ID: 14501379)
1. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate.
Szende B; Kéri G
Anticancer Drugs; 2003 Sep; 14(8):585-8. PubMed ID: 14501379
[TBL] [Abstract][Full Text] [Related]
2. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY
Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.
Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564
[TBL] [Abstract][Full Text] [Related]
4. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
Tejeda M; Gaal D; Barna K; Csuka O; Kéri G
Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719
[TBL] [Abstract][Full Text] [Related]
5. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.
Kéri G; Erchegyi J; Horváth A; Mezõ I; Idei M; Vántus T; Balogh A; Vadász Z; Bökönyi G; Seprõdi J; Teplán I; Csuka O; Tejeda M; Gaál D; Szegedi Z; Szende B; Roze C; Kalthoff H; Ullrich A
Proc Natl Acad Sci U S A; 1996 Oct; 93(22):12513-8. PubMed ID: 8901613
[TBL] [Abstract][Full Text] [Related]
6. Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
Szende B; Horváth A; Bökönyi G; Kéri G
Br J Cancer; 2003 Jan; 88(1):132-6. PubMed ID: 12556972
[TBL] [Abstract][Full Text] [Related]
7. Superactive octapeptide somatostatin analogs containing tryptophan at position 1.
Cai RZ; Karashima T; Guoth J; Szoke B; Olsen D; Schally AV
Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2502-6. PubMed ID: 2882520
[TBL] [Abstract][Full Text] [Related]
8. Influence of various administration routes on the antitumor efficacy ofTT-232, a novel somatostatin analog.
Tejeda M; Gaal D; Schwab RE; Pap A; Szúts T; Keri G
Anticancer Res; 2000; 20(2A):1023-7. PubMed ID: 10810391
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, conformational analysis and bioactivity of Lan-7, a lanthionine analog of TT-232.
Li H; Jiang X; Howell SB; Goodman M
J Pept Sci; 2000 Jan; 6(1):26-35. PubMed ID: 10674717
[TBL] [Abstract][Full Text] [Related]
10. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
11. A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells.
Szegedi Z; Takács J; Szende B; Vadász Z; Horváth A; Gulyás E; Tóth G; Peták I; Bocsi J; Kéri G
Endocrine; 1999 Feb; 10(1):25-34. PubMed ID: 10403568
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia.
Pintér E; Helyes Z; Németh J; Pórszász R; Pethö G; Thán M; Kéri G; Horváth A; Jakab B; Szolcsányi J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):142-50. PubMed ID: 12122501
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models.
Tejeda M; Gaál D; Csuka O; Kéri G
Anticancer Res; 2005; 25(1A):325-30. PubMed ID: 15816555
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship studies of novel somatostatin analogs with antitumor activity.
Kéri G; Mezô I; Vadász Z; Horváth A; Idei M; Vántus T; Balogh A; Bökönyi G; Bajor T; Teplán I
Pept Res; 1993; 6(5):281-8. PubMed ID: 7903057
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of receptors for somatostatin in various tumors using different analogs.
Srkalovic G; Cai RZ; Schally AV
J Clin Endocrinol Metab; 1990 Mar; 70(3):661-9. PubMed ID: 1968467
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
Cai RZ; Szoke B; Lu R; Fu D; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1896-900. PubMed ID: 2869490
[TBL] [Abstract][Full Text] [Related]
18. Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin.
Cassoni P; Muccioli G; Marrocco T; Volante M; Allia E; Ghigo E; Deghenghi R; Papotti M
J Endocrinol Invest; 2002 Apr; 25(4):362-8. PubMed ID: 12030609
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Milovanovic SR; Radulovic S; Groot K; Schally AV
Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.
Tejeda M; Gaál D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2006; 26(4B):3011-5. PubMed ID: 16886628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
